Breaking News, Financial News

Financial Report: Charles River 3Q

Preclinical Services up 6% in the quarter

Charles River Laboratories

3Q Revenues: $278.7 million (flat)

3Q Earnings: $22.2 million (+17%)

YTD Revenues: $849.4 million (flat)

YTD Earnings: $79.3 million (-4%)

Comments: Research Models and Services (RMS) segment sales were $166.5 million in the quarter, down 3%. Preclinical Services (PCS) sales were $112.2 million, up 6%. Income from continuing operations for the quarter was $22.4 million, compared to $18.9 million in 3Q11.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters